OncoMatch/Clinical Trials/NCT06759701
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
Is NCT06759701 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Tirzepatide for diabetes.
Treatment: Tirzepatide — The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage T2C, OR LOWER (NCCN)
Excluded: Stage PT3A OR HIGHER
Grade: Grade group 2Grade group 3 (Gleason)
Clinical T2b-T2c or lower disease; Gleason Grade group 2 or 3 on biopsy; PSA ≤20 ng/mL
Demographics
Prior therapy
Cannot have received: androgen deprivation
Any prior androgen deprivation, chemotherapy, surgery, or radiation for PCa
Cannot have received: chemotherapy
Any prior androgen deprivation, chemotherapy, surgery, or radiation for PCa
Cannot have received: surgery
Any prior androgen deprivation, chemotherapy, surgery, or radiation for PCa
Cannot have received: radiation therapy
Any prior androgen deprivation, chemotherapy, surgery, or radiation for PCa
Cannot have received: bariatric surgery
Previous or planned surgical treatment for obesity
Cannot have received: weight loss medication
use of a medication that promotes weight loss within 90 days before screening
Lab requirements
Kidney function
eGFR ≥30 as determined using standard MD Anderson laboratory measures
Liver function
ALT ≤3.0X ULN for the reference range; ALP ≤1.5X ULN for the reference range; total bilirubin ≤1.2X ULN for the reference range (except for cases of known Gilbert's Syndrome); nonalcoholic fatty liver disease allowed if ALT ≤3.0X ULN
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30...ALT >3.0X ULN...ALP >1.5X ULN...total bilirubin >1.2X ULN (except for cases of known Gilbert's Syndrome)...Participants with nonalcoholic fatty liver disease are eligible to participate in this trial if their ALT level is ≤3.0X the ULN for the reference range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06759701 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T2C or OR LOWER is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages